Audeo Oncology, a US-based cancer treatment company wholly owned by Alchemica, has filed to raise up to $60m in its initial public offering.
Alchemia acquired Audeo in 2006, when it was known as Meditech Research, paying $16.9m in shares plus a $2m loan.
The flotation is advised by US-based banks Leerink Swann and Oppenheimer.